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Evaluation of the Effects of Sildenafil
Citrate (Viagra) on Vertebral Artery Blood
Flow in Patients with Vertebro-Basilar
Insufficiency
Objective: To investigate the effects of sildenafil citrate (Viagra) on the verte-
bral artery blood flow of patients with vertebro-basilar insufficiency (VBI) using
color duplex sonography (CDS). 
Materials and Methods: The study included 21 patients with VBI (aged 31-76;
mean 61.0 ± 10.5 yrs). We administered a 50 mg oral dose of sildenafil citrate to
all patients. Next, we measured the peak systolic velocity (Vmax), end diastolic
velocity (Vmin), resistive index (RI), pulsatility index (PI), diameter, area, and flow
volume (FV) of vertebral arteries using CDS before the administration of sildenafil
citrate; 45 minutes after, and 75 minutes after administration. Statistical testing
was performed using SPSS for windows version 11.0. The statistical test used to
determine the outcome of the analysis was the repeated measures analysis of
variance (ANOVA) test. 
Results: Compared to the baseline values, the vertebral artery diameter, area,
and FV increased significantly following the administration of sildenafil citrate.
The diameter, area and FV increased from 3.39 mm at 45 minutes to 3.64 mm at
75 minutes, 9.43 cm
2 to 10.80 cm
2 at 45 minutes and 10.81 cm
2 at 75 minutes, as
well as from 0.07 L/min at baseline to 0.09 L/min at 45 minutes and unchanged at
75 minutes, respectively.
Conclusion: Sildenafil citrate elicited a significant effect on vertebral artery
diameter, area and FVs.
ertebro-basilar insufficiency (VBI) is a clinical syndrome, which is related
to blood flow insufficiency in the vertebral, basilar and posterior cerebral
artery feeding territories. Frequent symptoms of hemodynamic insuffi-
ciency in the vertebrobasilar artery system may result from altered blood flow rates to
the vestibulocochlear system, producing peripheral receptive hearing loss, tinnitus,
vertigo and dizziness (1). The examination of vertebral artery (VA) blood flow by
color duplex sonography (CDS) is demonstrated to be a safe and noninvasive method.
Usually, flow volume (FV) or velocity of VAs is used for the evaluation of VBI. These
properties enabled us to utilize this technique in the diagnosis of VBI (1, 2).
Sildenafil citrate (Viagra) is a highly selective inhibitor of the cGMP-degrading
intracellular enzyme phosphodiesterase 5 (PDE5) (3). Inhibition of PDE5 induces
cGMP accumulation in the penile tissue and this process causes an erection. This drug
has emerged as the safest oral vasoactive drug in the treatment of erectile dysfunction
(ED). The success rate of sildenafil citrate in ED is varies between 60% and 85%,
which is comparable with other vasoactive injectable agents used to treat ED (4). This
high success rate and easy use are the major reasons for the worldwide popularity of
this drug in the treatment of ED. 
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VSeveral studies investigated the effect of sildenafil citrate
on cerebral, cavernous and coronal arteries (3, 5, 6). In
addition, beneficial effects of sildenafil were reported in
the treatment of primary pulmonary hypertension (7). The
effects of this drug on VAs have not been studied before.
The aim of this study was to investigate the early phase
effects of this agent on VA blood flow in patients with VBI
by using CDS. 
MATERIALS AND METHODS
A total of 26 patients were screened for this study. Five
patients were excluded due to congestive heart disease,
acute ischemic heart disease, stroke or myocardial infarc-
tion, concomitant treatment with nitrates or presence of
hypotension, previously described migraine attack, stenosis
of the VA, which was diagnosed by angiography, and co-
morbid conditions. Finally, 21 patients (15 females, 6
males) with VBI (aged 31-74, mean 61.0 ± 10.5 years)
volunteered to participate in this study. An experienced
neurologist examined patients for symptoms like vertigo,
gait disturbance, drop attack and positional vertigo, which
were clinical diagnostic criteria of VBI. The radiologic
criterion for VBI was accepted as lower than 200 mL/min
FV of VAs (2). All of the patients’ bilateral VAs were
examined in the supine position with the head slightly
turned on the opposite side using a linear transducer (6-13
MHz broadband transducer). VA measurements were
executed between 3th and 4th cervical vertebra. The
research protocol was approved by the Local Ethics
Committee and all patients signed a written informed
consent form. 
All the Doppler sonographic measurements were
performed by the same operator using a Toshiba Aplio
SSA-770A/80 scanner (Tokyo, Japan). The basal values of
the peak systolic velocity (Vmax), end diastolic velocity
(Vmin), resistive index (RI), pulsatility index (PI), bilateral
VA diameter, area and FV were measured by a radiologist
experienced in longitudinal plane images using automatic
measurement settings. All parameters measured from the
right and left VAs were averaged to calculate the mean
values. The basal measurements of VA were taken at
operating room. Following a 15 minutes rest time in supine
position, 50 mg of sildenafil citrate was administered orally
to each patient. Because of maximum plasma concentra-
tion of sildenafil is achieved within 30-120 minutes
(average 60 minute), the CDS evaluation for all of the
above mentioned parameters were repeated at 45 minutes
and 75 minutes after the administration of the drug. The
Doppler angle was constantly sustained between 45 and 60
degrees in the evaluated arteries. The intravascular FV was
calculated as the product of the angle-corrected time
averaged flow velocity (TAFV) and the cross-sectional area
(A) of the circular vessel using the formula: FV= TAFV x
A. The cross-sectional areas of the VA were determined as
the distance between in the internal layers of the parallel
walls (2). 
All statistical analyses were performed using SPSS for
windows version 11.0 (SPSS, Chicago, IL). Statistical
analyses of data collected before the initial drug adminis-
tration, and at 45 minutes and 75 minutes after drug
administration, were performed using the repeated
measures variance analysis (ANOVA) test. Statistical
significance was set at p < 0.05.
RESULTS
Significant changes were observed in six of the 14
measured parameters. Compared to baseline values,
diameter, area, and FV of the VAs increased following the
administration of sildenafil citrate. The diameter increased
from 3.39 mm at baseline to 3.64 mm at 45 minutes and
75 minutes, the area increased from 9.43 cm
2 at baseline to
10.80 cm
2 at 45 minutes and 10.81 cm
2 at 75 minutes, and
the FV increased from baseline 0.07 L/min to 0.09 L/min
at 45 minutes and was unchanged at 75 minutes. Between
45 minutes and 75 minutes, the values were not signifi-
cantly different for the diameter, area and FV. The values
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Table 1. Peak Systolic Velocity (Vmax), End Diastolic Velocity (Vmin), Resistive Index (RI), Pulsatility Index (PI), Diameter, Area
and Flow Volume of Vertebral Arteries
Parameters Baseline Post Dosage (45 minutes) Post Dosage (75 minutes)
Vmax (cm/sec) 41.25 ± 17.50 43.50 ± 20.00 41.54 ± 25.73
Vmin (cm/sec)    12.01 ± 5.66 12.74 ± 6.03 12.41 ± 9.69
RI      00.57 ± 0.11 00.60 ± 0.11 00.57 ± 0.13
PI    01.36 ± 0.30 01.40 ± 0.49 01.37 ± 0.39
Diameter (mm)   03.39 ± 0.69 03.64 ± 0.69* 03.64 ± 0.73
�
Area (mm
2) 09.43 ± 3.75 10.80 ± 3.83* 10.81 ± 4.37
�
Volume (L/min) 00.07 ± 0.04 00.09 ± 0.06* 00.09 ± 0.08
�
Note.─ *Baseline versus post dosage 45 minutes, 
�Baseline versus post dosage 75 minutes, p < 0.05of Vmax, Vmin, RI and PI were not different between
baseline and 45 minutes and 75 minutes (Table 1). 
After usage of sildenafil citrate, we observed some
changes on VBI symptoms. In our patients, the most
prominent symptoms included vertigo and dizziness. Five
patients reported reduced vertigo and dizziness as well as
partial recovery of gait disturbance for one patient in the
clinical examination. We did not observe any changes in
other VBI symptoms during the CDS examination. The
most important complaint from the usage of sildenafil
citrate was headaches in 17 of 21 patients. We did not
observe significant discomfort in the patients evaluated
except for minor side effects (i.e, nausea, flushing etc.) in a
small portion of the study population. 
DISCUSSION
Vertebro-basilar insufficiency is a common cause of
vestibular disorder, which seen in middle aged and elderly
patients. Arteriosclerosis, embolic incidents and compres-
sive effects of cervical spondylosis play the most important
roles in the etiology of VBI (1, 2). There are many invasive
and noninvasive procedures such as the traditional angiog-
raphy, magnetic resonance angiography (MRA) and CDS,
which provide helpful information about abnormalities in
the vertebrobasilar system (8). Evaluation of VAs using
CDS is noninvasive, quick and easily applicable, and
provides valuable information on the vertebrobasilar
system. There are many studies related to VBI in the litera-
ture. In a recent study, Acar et al. (2) compared the VA
velocity and FV measurements in the diagnosis of VBI
using CDS. The authors concluded that for the diagnosis of
VBI, the measurement of volume in addition to velocity is
more valuable in the detection of moderately damped VA
FVs (2). 
Sildenafil citrate is rapidly absorbed, reaching maximum
plasma concentrations within one hour after oral usage,
and has a mean terminal half-life is 3 to 5 hours (9).
Herrmann et al. (6) showed minimal reductions in systemic
and pulmonary artery pressure without any serious cardio-
vascular effects after sildenafil usage. Kocakoc et al. (10)
reported that sildenafil had no significant effect on aortic
and superior mesenteric artery blood flow in ED patients.
They did however observe mild blood flow alteration in
the carotid arteries (10). In a recent study performed in
dogs, significant increases were observed for the Vmax and
RI of the aorta as well as decreases in the right carotid and
left segmental renal artery Vmax (11).
PDE type 5 is present in vascular smooth muscle and
platelets. A recent animal study showed that PDE5 is
present in the brain tissue, cerebellum and hippocampus
(12). In this study, PDE inhibitors caused cerebral artery
dilatation, whereas; Kruuse et al. (3) found that sildenafil
usage had no significant effects on cerebral blood flow and
the diameter of cerebral and extracerebral arteries.
Arnavaz et al. (9) investigated the effects of sildenafil
citrate on the middle cerebral arteries. As in the previous
studies, the researchers observed no significant effects;
rather they found an insignificant decreasing trend in blood
flow rates.
In our study, diameter, area and FV of VA significantly
increased after sildenafil usage. This alteration might be
related to the amount of PDE5 receptor on VAs.
According to the aforementioned studies, sildenafil may
have different roles in human arteries, which potentially
depend on PDE5 receptor levels of each artery. 
Sastry et al. (7) investigated the effect of sildenafil on the
pulmonary artery in primary pulmonary hypertension.
They showed vasodilatation in the pulmonary artery and a
decrease in pulmonary vascular resistance. They claimed
that this drug may represent the first line of therapy in
these patients (7). In another report, milrinone, a PDE3
inhibitor, improved clinical outcome in patients with
subarachnoidal hemorrhage by a mechanism of reverse
vasospasm (13). 
In a recent animal study, administration of sildenafil to
rats with embolic stroke enhanced angiogenesis and
selectively increased cerebral blood flow in the ischemic
boundary, improved the neurological functional recovery
compared to the control group (14). In another study,
Atalay et al. (15) analysed the effects of sildenafil citrate
on the cerebral vasospasm. The vasodilatory effect of
sildenafil citrate was observed to be significant on normal
cerebral vessels and following subarachnoid hemorrhage-
induced vasospasm. According to these results, sildenafil
citrate may useful in the treatment of cerebrovascular
disease.
In conclusion, values of diameter, area and FV of VAs
increased after administration of sildenafil citrate
compared to baseline values. Due to its vasodilatatory
effects, sildenafil might be useful to improve symptoms of
VBI. These findings should be further confirmed by
prospective studies in large patient groups.
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